This article is more than 5 years old. Information may no longer be current.
Bioventus acquires BioStructures and expands orthobiologic offerings
Click Here to Manage Email Alerts
Bioventus LLC recently announced it has acquired BioStructures LLC, a developer and marketer of bioresorbable bone graft products for spinal and orthopedic surgical applications. However, terms of the acquisition were not disclosed.
Bioventus LLC will acquire the portfolio of BioStructures LLC products and all current research and development. In addition, employees of BioStructures LLC will be given offers to join Bioventus LLC, according to a press release.
“The acquisition of BioStructures aligns with our strategy to be a leader in orthobiologics, building on the launch of the Bioventus Surgical business with the OsteoAMP acquisition in 2014, and our longer term development of the next generation [bone morphogenetic protein] BMP,” Tony Bihl, chief executive officer of Bioventus LLC, said in a press release. “This now gives Bioventus a broad offering of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons and hospitals.”
The acquired portfolio includes BioStructure’s Interface Bioactive Bonegraft, a synthetic graft used in osseous defect repair, and Signafuse Bioactive Bonegraft Putty, which is comprised of a bi-phasic mineral composite combined with the company’s bioactive glass and resorbable polymer carrier. In addition, the portfolio includes synthetic, allograft, collagen, and demineralized bone matrix products.
Reference: